Clinical trial
Redo AF Sub Study (of the Pure EP 2.0 Main Study)
NCT04964440 is registered in ClinicalTrials.gov with BioSig Technologies, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Redo AF Sub Study (of the Pure EP 2.0 Main Study)
- Lead sponsor
- BioSig Technologies, Inc.
- Phase
- Observational
- Overall status
- Completed
- Start date
- March 3, 2021
- Completion date
- January 29, 2022
- Enrollment
- 20 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
atrial fibrillation recurrent